Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The Primary Objective: To observe and determine the safety and tolerance of allogeneic
hepatocyte transplantation in patients with liver cirrhosis and to establish the
maximum-tolerated dose (MTD) and evaluate the dose-limiting toxicities (DLTs).
The Secondary Objective: To observe the therapeutic efficacy of allogeneic hepatocyte
transplantation for liver cirrhosis.